Rigel Pharmaceuticals Launches VEPPANU™ for Breast Cancer Treatment: A New Hope

Rigel Pharmaceuticals Launches VEPPANU™ for ER+/HER2- Metastatic Breast Cancer

Rigel Pharmaceuticals, Inc. has made a significant announcement with the launch of its groundbreaking treatment, VEPPANU™ (vepdegestrant), designed specifically for adult patients suffering from estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer (mBC). This FDA-approved drug is now available by prescription in the United States and promises to be an essential addition to existing cancer therapies.

What is VEPPANU™?

VEPPANU™ is recognized as the first and only FDA-approved PROTAC (PROteolysis TArgeting Chimera), a unique class of drugs that work differently from traditional treatments. Rather than merely inhibiting cancer-causing proteins, PROTACs utilize the body's natural system to selectively degrade these harmful proteins. This innovative approach offers a new mechanism for fighting cancer, providing hope to patients whose conditions have progressed despite standard therapies.

Clinical Efficacy and Trials

In pivotal clinical trials, VEPPANU™ was well tolerated by patients and indicated a statistically significant improvement in progression-free survival when compared to fulvestrant. Such a finding is paramount, particularly for individuals who have experienced disease progression following at least one line of endocrine therapy. The promising results from these studies underscore VEPPANU™'s potential as a game-changer in the treatment of advanced breast cancer.

Rigel’s Commitment to Patients

Raul Rodriguez, Rigel’s President and CEO, emphasized the importance of this launch, stating, “The commercial introduction of VEPPANU™ is a crucial milestone, not only for Rigel but importantly for those battling ER+/HER2-, ESR1-mutated breast cancer.” With a robust marketing and patient support strategy in place, Rigel expects a successful rollout of the drug, showcasing their dedication to enhancing patient care while focusing on their long-term growth objectives.

What Patients Need to Know

The recommended dosage for VEPPANU™ is 200 mg, taken orally once daily. It is currently available through specialty pharmacies and distributors across the U.S. and Puerto Rico, priced at approximately $29,400 for a 30-day supply. Recognizing the financial burden this treatment may create, Rigel Pharmaceuticals is committed to supporting patients through RIGEL ONECARE®, a comprehensive patient support initiative that offers help with insurance navigation and potential financial assistance for eligible individuals.

Breast Cancer Landscape

Breast cancer remains the most prevalent cancer among women, accounting for approximately 70% of cases being ER+/HER2-. Unfortunately, many patients develop resistance to traditional therapies, which complicates treatment and leads to poorer outcomes. With the new approval of VEPPANU™, Rigel Pharmaceuticals aims to fill a significant gap in treatment options for the 50% of patients who acquire ESR1 mutations and face limited options post-endocrine therapy.

Conclusion

The release of VEPPANU™ is not only a significant achievement for Rigel Pharmaceuticals but also a hopeful development for patients suffering from advanced or metastatic breast cancer. It exemplifies the ongoing evolution of cancer treatments and underscores the need for continuous innovation in addressing unmet medical needs in oncology. For more information on how to access VEPPANU™, visit www.RIGELONECARE.com or contact their patient support line at 833-RIGELOC (833-744-3562).

By advancing medical research and providing new therapeutic options, Rigel is positioning itself at the forefront of biotechnology with a clear commitment to improving the lives of patients with serious health conditions.